Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial.

Sustained MADRS response (MADRS≤12 for at least the last two consecutive visits during double-blind treatment) rates were numerically higher for all active treatment groups compared with placebo, although the differences did not reach statistical significance (Table 2 ).

also in 111,027 other papers